2649854-92-0
Chemical Structure
Nisevokitug
Synonym(s): NIS-793
- CAS No.: 2649854-92-0
- Formula:N/A
- Molecular Weight:(146.254 kDa)
SMILES: [Nisevokitug]
Biological Activity: Nisevokitug (NIS-793) is a humanized IgG2λ monoclonal antibody and an inhibitor of the TGF-β signaling pathway. Nisevokitug blocks the binding of TGF-β to the membrane-bound TGF-βR1/TGF-βR2 receptors, inhibits both Smad-dependent and Smad-independent downstream cascade signaling, downregulates fibrosis-related genes, and reverses the TGF-β-mediated immunosuppressive microenvironment. Nisevokitug can be used in the research of diseases such as pancreatic ductal adenocarcinoma, colorectal cancer, myelofibrosis, and myelodysplastic syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nisevokitug | 97.00% | Nisevokitug (NIS-793) is a humanized IgG2λ monoclonal antibody and an inhibitor of the TGF-β signaling pathway. Nisevokitug blocks the binding of TGF-β to the membrane-bound TGF-βR1/TGF-βR2 receptors, inhibits both Smad-dependent and Smad-independent downstream cascade signaling, downregulates fibrosis-related genes, and reverses the TGF-β-mediated immunosuppressive microenvironment. Nisevokitug can be used in the research of diseases such as pancreatic ductal adenocarcinoma, colorectal cancer, myelofibrosis, and myelodysplastic syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Guo W, et al. Targeting the TGF-β signaling pathway: an updated patent review (2021-present). Expert opinion on therapeutic patents. 2024 Mar;34(3):99-126. [Content Brief]
- [2]. Watrin T, et al. The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN). Leukemia & lymphoma. 2026 Jan;67(1):17-26. [Content Brief]
Keywords
